Starling Oncology (STLNW) Other financing activities (2020 - 2026)

Starling Oncology (STLNW) has reported Other financing activities for 4 consecutive years, with $90000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities changed N/A year-over-year to $90000.0; the trailing twelve-month figure through Jun 2026 stood at $111000.0 (down 99.28% YoY), and the FY2025 full-year result was $15.4 million, up 20378.67% from the prior year.
• Other financing activities climbed to $90000.0 in Q2 2026 per STLNW's latest filing, from $21000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $15.4 million in Q1 2025 and bottomed at $21000.0 in Q1 2026.
• Historically, Other financing activities has averaged $3.9 million across 3 years, with a median of $82500.0 in 2024.
• The widest YoY moves for Other financing activities: up 99.86% in 2026, down 99.86% in 2026.
• Over 3 years, Other financing activities stood at $75000.0 in 2024, then jumped by 20378.67% to $15.4 million in 2025, then slumped by 99.41% to $90000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $90000.0, $21000.0, and $15.4 million for Q2 2026, Q1 2026, and Q1 2025 respectively.